Artivion (NYSE:AORT) Rating Reiterated by Needham & Company LLC

Artivion (NYSE:AORT)‘s stock had its “buy” rating reissued by stock analysts at Needham & Company LLC in a research note issued to investors on Friday, Benzinga reports. They currently have a $30.00 target price on the stock. Needham & Company LLC’s price objective points to a potential upside of 11.73% from the company’s previous close.

AORT has been the subject of several other research reports. Stifel Nicolaus upped their price objective on Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, September 13th. Oppenheimer boosted their target price on shares of Artivion from $25.00 to $30.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. Finally, Lake Street Capital increased their price objective on shares of Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, July 2nd.

Artivion Price Performance

Shares of NYSE AORT opened at $26.85 on Friday. Artivion has a twelve month low of $12.16 and a twelve month high of $29.24. The company has a market cap of $1.12 billion, a PE ratio of -111.88 and a beta of 1.74. The business’s 50 day moving average price is $25.84 and its two-hundred day moving average price is $23.86. The company has a quick ratio of 4.04, a current ratio of 5.63 and a debt-to-equity ratio of 1.07.

Artivion (NYSE:AORT) last issued its quarterly earnings results on Thursday, August 8th. The company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.03 by $0.04. The business had revenue of $98.02 million for the quarter, compared to the consensus estimate of $97.70 million. Artivion had a positive return on equity of 3.81% and a negative net margin of 2.22%. On average, analysts predict that Artivion will post 0.2 EPS for the current year.

Insider Buying and Selling

In other news, SVP Jean F. Holloway sold 2,383 shares of the firm’s stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $25.76, for a total transaction of $61,386.08. Following the sale, the senior vice president now owns 165,099 shares in the company, valued at approximately $4,252,950.24. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other Artivion news, SVP Jean F. Holloway sold 3,167 shares of the stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $26.55, for a total value of $84,083.85. Following the completion of the sale, the senior vice president now owns 161,932 shares in the company, valued at approximately $4,299,294.60. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Jean F. Holloway sold 2,383 shares of the business’s stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $25.76, for a total transaction of $61,386.08. Following the transaction, the senior vice president now directly owns 165,099 shares in the company, valued at $4,252,950.24. The disclosure for this sale can be found here. In the last quarter, insiders have sold 24,679 shares of company stock valued at $626,518. Corporate insiders own 8.10% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of AORT. nVerses Capital LLC bought a new stake in shares of Artivion in the 2nd quarter worth $28,000. GAMMA Investing LLC lifted its holdings in Artivion by 38.6% in the 1st quarter. GAMMA Investing LLC now owns 1,814 shares of the company’s stock worth $38,000 after purchasing an additional 505 shares in the last quarter. RiverPark Advisors LLC bought a new stake in Artivion in the 2nd quarter valued at $55,000. Register Financial Advisors LLC bought a new stake in Artivion in the 1st quarter worth approximately $114,000. Finally, Allspring Global Investments Holdings LLC lifted its position in Artivion by 291.3% during the first quarter. Allspring Global Investments Holdings LLC now owns 5,580 shares of the company’s stock valued at $118,000 after purchasing an additional 4,154 shares during the last quarter. 86.37% of the stock is owned by hedge funds and other institutional investors.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.